MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$2,835K
Free Cash flow
$32,378K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Repayment of loan principal
    • Accounts payable, accrued and ot...
    • Amortization of premiums and dis...
    • Others
Negative Cash Flow Breakdown
    • Maturities of marketable securit...
    • Stock-based compensation
    • Other assets
    • Others
Cash Flow
2026-03-31
2025-09-30
2025-06-30
Net loss
35,731
-11,227
-30,260
Depreciation and amortization
-674
227
494
Stock-based compensation
-6,683
2,136
5,200
Amortization of premiums and discounts on marketable securities
-1,769
494
1,275
Amortization of debt discount and issuance costs and other non-cash interest
-238
37
201
Impairment loss of right-of-use asset
-
0
0
Loss on fixed asset write-off
119
-
-
Reclassification of currency translation loss
-
282
-
Gain on sale of nonfinancial asset
1,000
-
-
Gain on disposition of fixed assets
5
4
-
Prepaid expenses and other current assets
-1,042
432
-1,390
Other assets
2,415
-674
-1,741
Accounts payable, accrued and other current liabilities
3,908
-426
-6,322
Operating lease assets and liabilities
-1,098
603
1,154
Net cash used in operating activities
32,370
-9,830
-29,985
Purchases of property and equipment
-8
0
8
Proceeds from sale of nonfinancial asset
1,000
-
-
Proceeds from sale of fixed assets
520
9
-
Purchases of marketable securities
-
14,297
28,334
Maturities of marketable securities
-83,481
30,000
53,481
Net cash provided by investing activities
-39,322
15,712
25,139
Repayment of loan principal
-3,913
1,305
2,608
Proceeds from issuance of common stock under employee stock incentive plans
232
0
35
Net cash provided by (used in) financing activities
4,145
-1,305
-2,573
Effect of exchange rate changes on cash and cash equivalents
-28
-9
37
Net decrease in cash and cash equivalents
-2,835
4,568
-7,382
Cash and cash equivalents at the beginning of period
38,935
41,749
-
Cash and cash equivalents at the end of period
66,229
38,935
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net loss$35,731K Repayment of loanprincipal-$3,913K Proceeds from issuance ofcommon stock under...$232K Accounts payable,accrued and other...$3,908K Amortization of premiums anddiscounts on marketable...-$1,769K Operating lease assets andliabilities-$1,098K Prepaid expenses andother current assets-$1,042K Net cash used inoperating activities$32,370K Net cash provided by(used in) financing...$4,145K Canceled cashflow$11,015K Net decrease in cashand cash...-$2,835K Canceled cashflow$36,515K something is missing$42,631K Proceeds from sale ofnonfinancial asset$1,000K Proceeds from sale offixed assets$520K Purchases of property andequipment-$8K Stock-based compensation-$6,683K Other assets$2,415K Gain on sale ofnonfinancial asset$1,000K Depreciation andamortization-$674K Amortization of debt discountand issuance costs...-$238K Gain on dispositionof fixed assets$5K Net cash provided byinvesting activities-$39,322K Canceled cashflow$44,159K Effect of exchange ratechanges on cash and cash...-$28K Maturities of marketablesecurities-$83,481K

Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences, Inc. (KZR)